RAD21 (RAD21 Homolog, Cohesin Complex Subunit) encodes a key component of the cohesin complex, which is essential for sister chromatid cohesion, DNA repair, transcriptional regulation, and chromatin looping. The cohesin complex entraps sister chromatids from S phase until anaphase, ensuring proper chromosome segregation. Beyond its canonical role in cell division, cohesin (including RAD21, SMC1A, SMC3, STAG1/2) regulates gene expression by forming chromatin loops that bring distal enhancers into proximity with promoters[@marsoner2019].
Mutations in RAD21 are associated with Cornelia de Lange Syndrome (CdLS), sclerosing poikiloderma, and various cancers. Recent research has revealed that RAD21 dysfunction contributes to neurodegenerative diseases including Alzheimer's disease and Parkinson's disease[@wang2022].
|
|
| Gene Symbol |
RAD21 |
| Gene Name |
RAD21 Homolog, Cohesin Complex Subunit |
| Chromosome |
8q24.11 |
| NCBI Gene ID |
11124 |
| OMIM |
606462 |
| Ensembl ID |
ENSG00000164754 |
| UniProt ID |
Q9UQE5 |
| Protein Class |
Cohesin Complex Subunit |
| Associated Diseases |
Cornelia de Lange Syndrome, Sclerosing Poikiloderma, Cancer, Alzheimer's Disease |
¶ Structure and Biochemistry
RAD21 is a 581-amino acid protein with distinct functional regions:
- N-terminal domain: Interacts with SMC1A to form the cohesin ring
- Central region: Contains the essential cleavage sites for separase
- C-terminal domain: Binds to SMC3 and STAG1/2
The RAD21 protein forms a heterodimer with SMC1A that constitutes the core "cohesin ring" complex. This ring entraps sister chromatids during DNA replication and maintains cohesion until anaphase.
The canonical cohesin complex includes:
| Subunit |
Function |
| SMC1A |
ATPase, forms heterodimer with SMC3 |
| SMC3 |
ATPase, forms heterodimer with SMC1A |
| RAD21 |
Connects SMC heterodimer, forms "kleisin" ring |
| STAG1/2 |
Regulatory subunit, enables loader binding |
RAD21 is regulated by multiple modifications:
- Phosphorylation: By Polo-like kinases and Aurora B for proper chromosome behavior
- Acetylation: By Eco1/Ctf7 during S phase for establishment of cohesion
- Proteolytic cleavage: By separase (ESPL1) during anaphase to allow sister chromatid separation
The primary function of RAD21 is to maintain sister chromatid cohesion[@pradhan2022]:
- Loading: Cohesin is loaded onto DNA by the Scc2/4 complex during early S phase
- Ring closure: RAD21 closes the ring by connecting SMC1A and SMC3
- Cohesion establishment: Eco1 acetylates cohesin to stabilize the association
- Maintenance: Cohesin remains associated throughout S, G2, and early M phases
- Release: Separase cleaves RAD21 at anaphase onset
RAD21 participates in multiple DNA repair pathways[@kojic2020]:
Homologous recombination (HR):
- Cohesin recruitment to double-strand breaks
- Rad51-mediated strand invasion
- Resolution of recombination intermediates
Non-homologous end joining (NHEJ):
- Alternative pathway for DSB repair
- Requires proper cohesin dynamics
Checkpoint signaling:
- ATR/Chk1 activation at stalled forks
- Cohesin-dependent checkpoint maintenance
Beyond chromosome segregation, RAD21 regulates gene expression[@barra2023]:
Chromatin looping:
- Formation of topologically associating domains (TADs)
- Enhancer-promoter interactions
- Insulator function
Gene expression programs:
- Developmental transcription factors
- Neuronal activity-dependent genes
- Cell cycle regulators
RAD21 is ubiquitously expressed with highest levels in:
- Brain: Neurons in cortex, hippocampus, cerebellum
- Proliferating cells: Stem cells, cancer cells
- Hematopoietic tissues: Bone marrow, spleen
- Epithelial tissues: Intestine, skin
During brain development, RAD21 is essential for:
- Neural progenitor cell proliferation
- Neuronal differentiation
- Synaptogenesis
- Cortical layering
Heterozygous RAD21 mutations cause CdLS[@schaerer2021], characterized by:
| Feature |
Description |
| Inheritance |
Autosomal dominant |
| Incidence |
~1 in 10,000 |
| Core phenotype |
Developmental delay, dysmorphic features |
Clinical manifestations:
- Growth retardation: Prenatal and postnatal growth delay
- Intellectual disability: Variable severity, often moderate
- Dysmorphic features: Arched eyebrows, nasal anomalies, downturned mouth
- Limb anomalies: Upper limb reductions, brachycephaly
- Behavioral issues: Autism spectrum features, anxiety
Genotype-phenotype:
- Missense mutations → milder phenotype
- Truncating mutations → classic CdLS
- Mosaic mutations → variable presentation
Recessive RAD21 mutations cause:
- Poikiloderma with hyperkeratosis
- Vascular insufficiency
- Increased cancer risk
RAD21 functions as a tumor suppressor:
- Colorectal cancer: Loss-of-function mutations
- Breast cancer: Reduced expression, poor prognosis
- Leukemia: Chromosomal instability
RAD21 dysfunction contributes to AD through[@wang2022]:
Chromatin organization defects:
- Altered TAD structure
- Dysregulated gene expression
DNA repair impairment:
- Accumulation of DNA damage
- Increased mutation burden
Transcriptional dysregulation:
- Altered amyloid processing genes
- Tau pathology modifiers
Dopaminergic neuron vulnerability:
- Cohesin dysfunction affects mitochondrial genes
- Enhanced sensitivity to oxidative stress
Synucleinopathy:
- Altered chromatin states affect α-synuclein clearance
- Transcriptional dysregulation of degradation pathways
RAD21 dysfunction leads to:
- TAD boundary disruption: Altered chromatin architecture
- Enhancer-promoter miswiring: Ectopic gene expression
- Epigenetic dysregulation: Histone modification changes
Cohesin-deficient cells show:
- Increased spontaneous DNA damage
- Impaired checkpoint signaling
- Chromosomal instability
- Cellular senescence
In neurons, RAD21 loss causes:
- Altered activity-dependent gene expression
- Impaired synaptic plasticity genes
- Mitochondrial dysfunction
- Cell death pathways
Cohesin modulators:
- WAPL inhibitors (cohesin stabilizers)
- HDAC inhibitors
- Topoisomerase inhibitors
Gene expression correctors:
- BET inhibitors
- CDK9 inhibitors
- AAV-mediated RAD21 delivery: Potential for cohesinopathies
- CRISPR-based approaches: Allele-specific editing
- Ex vivo gene correction: Autologous stem cell therapy
| Biomarker |
Utility |
| Cohesin complex levels |
Disease monitoring |
| Chromatin accessibility |
Functional assessment |
| DNA damage markers |
Cellular stress |
| Transcriptional profiles |
Gene expression changes |
Current priorities include:
- Mechanistic studies: Understanding RAD21's neuron-specific functions
- Therapeutic development: Identifying compounds that enhance cohesin function
- Biomarker development: Creating tests for diagnosis and monitoring
- Aging research: Cohesin decline in normal aging
¶ Mermaid Diagram: RAD21 Functions and Disease
flowchart TD
A["RAD21 Protein"] --> B["Sister Chromatid Cohesion"]
A --> C["DNA Repair"]
A --> D["Transcriptional Regulation"]
B --> B1["Cohesin Ring Formation"]
B1 --> B2["Chromosome Segregation"]
B2 --> B3["Genomic Stability"]
C --> C1["Double-Strand Break Repair"]
C --> C2["Checkpoint Signaling"]
C1 --> C3["Genome Integrity"]
D --> D1["Chromatin Looping"]
D1 --> D2["Enhancer-Promoter Interaction"]
D2 --> D3["Gene Expression Control"]
B3 --> E["Normal Cell Division"]
C3 --> E
D3 --> F["Cellular Homeostasis"]
G["RAD21 Mutations"] --> H["Cornelia de Lange Syndrome"]
G --> I["Cancer Predisposition"]
G --> J["Neurodegeneration"]
J --> K["Alzheimer's Disease"]
J --> L["Parkinson's Disease"]
K --> M["Chromatin Dysregulation"]
K --> N["DNA Damage Accumulation"]
L --> M
L --> N
L --> O["Transcriptional Alterations"]
style E fill:#e8f5e9
style H fill:#fff3e0
style K fill:#ffcdd2
style L fill:#ffcdd2
RAD21 testing is available for:
- Cornelia de Lange syndrome diagnosis: Panel testing
- Cancer predisposition assessment: Germline testing
- Research applications: Functional studies
- Epigenetic therapies: HDAC inhibitors to modulate cohesin function
- Gene therapy: AAV-mediated RAD21 delivery
- Synthetic lethality: PARP inhibitors in cohesin-deficient cancers
Future research directions include:
- Understanding neuron-specific cohesin functions
- Developing cohesin-targeted therapeutics
- Biomarker development for diagnosis and monitoring
¶ Chromatin Organization and Brain Function
The cohesin complex plays essential roles in chromatin organization that are critical for normal brain function. Understanding how cohesin dysfunction contributes to neurodegenerative diseases reveals important connections between genome organization and neuronal health.
Topologically Associating Domains (TADs)
Cohesin contributes to TAD formation in neurons:
- Loop extrusion: Cohesin extrudes DNA loops, creating TAD boundaries
- Insulator function: CTCF-cohesin complexes define domain boundaries
- Enhancer-promoter insulation: Proper insulation prevents aberrant gene activation
- Brain-specific TADs: Neurons have specialized TAD organization
Gene Expression Programs
Cohesin regulates critical neuronal gene programs:
- Activity-dependent genes: Immediate-early genes require cohesin function
- Developmental transcription factors: Neuronal differentiation genes
- Synaptic plasticity genes: Activity-regulated synaptic function genes
- Cell identity genes: Maintaining neuronal identity
Neurons are particularly vulnerable to DNA damage due to their non-dividing state and high metabolic activity. RAD21 plays crucial roles in maintaining genomic integrity.
Double-Strand Break Repair
Cohesin facilitates DNA double-strand break repair:
- Damage sensing: Cohesin rapidly localizes to DSB sites
- Checkpoint activation: Cohesin-dependent checkpoint signaling
- Repair pathway choice: Cohesin influences HR vs NHEJ decisions
- End resection: Cohesin promotes DNA end resection for HR
Neuronal Vulnerability
Neurons face unique DNA damage challenges:
- Oxidative stress: High metabolic rate generates reactive oxygen species
- Transcription burden: High transcriptional activity increases susceptibility
- Limited repair capacity: Post-mitotic neurons have constrained repair
- Accumulation: Lifetime DNA damage accumulation
RAD21 interacts with epigenetic machinery:
Histone Modifications
- Histone acetylation: Cohesin cooperates with histone acetyltransferases
- Histone methylation: Interactions with polycomb and trithorax complexes
- Chromatin remodeling: Coordination with ATP-dependent remodelers
DNA Methylation
- Cohesin and methylation: Mutual reinforcement of chromatin states
- Imprinting regulation: Cohesin in genomic imprinting
- X-inactivation: Cohesin in X chromosome inactivation
Pharmacological Approaches
- WAPL inhibitors: Stabilize cohesin on DNA to enhance chromatin interactions
- HDAC inhibitors: Modulate cohesin function through histone modifications
- BET inhibitors: Target transcription programs dependent on cohesin
Rationale for Therapeutic Intervention
- Enhancing chromatin function: Improving gene expression programs
- DNA repair enhancement: Boosting genomic maintenance
- Reducing DNA damage accumulation: Preventing neuronal loss
Viral Vector Delivery
- AAV-mediated RAD21 expression: Restoring RAD21 function
- CRISPR-based gene editing: Correcting pathogenic mutations
- Allele-specific approaches: Targeting specific mutations
Challenges and Considerations
- Delivery to neurons: Crossing the blood-brain barrier
- Expression levels: Achieving appropriate RAD21 dosage
- Safety concerns: Avoiding overexpression effects
Disease Biomarkers
| Biomarker |
Source |
Application |
| Cohesin complex levels |
Brain tissue, CSF |
Diagnostic markers |
| Chromatin accessibility |
Blood cells |
Functional assessment |
| DNA damage markers |
CSF, blood |
Disease progression |
| Transcriptional profiles |
Blood, tissue |
Gene expression changes |
Monitoring Treatment Response
- Cohesin function assays: Measuring chromatin loop formation
- Gene expression panels: Tracking disease-relevant genes
- Imaging biomarkers: MRI-based chromatin organization
Conditional Knockout Models
Brain-specific Rad21 knockout mice reveal:
- Neuronal development defects: Impaired neuronal differentiation
- Synaptic dysfunction: Altered synaptic plasticity
- Behavioral abnormalities: Learning and memory deficits
- Progressive neurodegeneration: Age-dependent cell loss
Transgenic Models
Models expressing mutant RAD21:
- Mimic patient mutations: Expressing CdLS-associated variants
- Conditional expression: Temporal and spatial control
- Phenotypic characterization: Comprehensive behavioral analysis
Neurobiological Studies
- Circuit mapping: Altered connectivity patterns
- Electrophysiology: Synaptic transmission abnormalities
- Histopathology: Brain region-specific degeneration
Therapeutic Testing
- Pharmacological interventions: Testing cohesin modulators
- Gene therapy approaches: Viral delivery studies
- Behavioral rescue: Functional improvement assessments
- SMC1A (Structural Maintenance of Chromosomes 1A) — ATPase subunit
- SMC3 (Structural Maintenance of Chromosomes 3) — ATPase subunit
- STAG1 (Cohesin Component STAG1) — Regulatory subunit
- STAG2 (Cohesin Component STAG2) — Alternative regulatory subunit
Loading Complex
- SCC2 (NIPBL) — Cohesin loader component
- SCC4 (MAU2) — Cohesin loader component
Disassembly Factors
- WAPL (Wings Apart-Like) — Cohesin release factor
- PDS5A/B — Cohesin-associated proteins
Chromatin Regulators
- CTCF — Insulator protein, cooperates with cohesin
- NIPBL — Cohesin loader, mutations cause CdLS
Neurodegeneration Pathways
- DNA repair proteins: ATR, BRCA1, RAD51
- Transcription factors: CTCF, YY1, REST
- Chromatin remodelers: CHD4, ISWI complexes
- Epigenetic modifiers: HDACs, DNA methyltransferases
¶ Cohesin Loading and Release Cycle
Loading Phase
- Scc2/4 recruitment: Loading complex binds to DNA
- Cohesin engagement: RAD21 connects SMC1A and SMC3
- Ring closure: Cohesin entraps DNA
- ATP hydrolysis: Energy-dependent loading
Maintenance Phase
- WAPL regulation: WAPL prevents premature release
- Stable association: Cohesin maintains DNA entanglement
- Chromatin loops: Loop extrusion establishes TADs
- Dynamic remodeling: Loops reorganize with activity
Release Phase
- WAPL displacement: PDS5 displaces WAPL
- Cohesin cleavage: Separase cleaves RAD21
- DNA release: Chromosome segregation complete
- Recycling: New cohesin loading for next cell cycle
Neurons have unique cohesin dynamics:
Non-Dividing Cell Considerations
- Maintenance function: Cohesin remains bound without cell division
- Dynamic remodeling: Activity-dependent loop reorganization
- Limited turnover: Stable cohesin complexes
- Stress responses: Cohesin in neuronal stress adaptation
Functional Implications
- Activity-dependent transcription: Rapid gene expression changes
- Synaptic plasticity: Chromatin reorganization with learning
- DNA repair: Cohesin in DNA damage response
- Aging effects: Declining cohesin function with age
¶ Genetic Testing and Counseling
Diagnostic Testing
- Panel testing: Comprehensive CdLS gene panels
- Exome sequencing: Targeted analysis
- Copy number analysis: Detecting deletions/duplications
Family Counseling
- Inheritance patterns: Autosomal dominant vs. recessive
- Carrier testing: Identifying at-risk family members
- Prenatal options: Preimplantation and prenatal diagnosis
Clinical Monitoring
- Neurological assessment: Regular cognitive evaluations
- Developmental tracking: Monitoring developmental progress
- Systemic complications: Addressing associated medical issues
Therapeutic Interventions
- Symptomatic treatments: Targeting specific symptoms
- Rehabilitative therapies: Physical, occupational, speech therapy
- Behavioral interventions: Managing autism and behavioral features
- Neuron-specific functions: How does RAD21 function differ in neurons?
- Disease mechanisms: What are the precise mechanisms in AD/PD?
- Therapeutic targets: What are the best intervention points?
- Biomarkers: What reliable biomarkers exist?
- Single-cell approaches: Understanding cell-type specificity
- Spatial genomics: Mapping chromatin organization in brain
- iPSC models: Patient-derived neuronal models
- CRISPR screens: Identifying genetic modifiers
- Small molecule modulators: Developing cohesin-targeted drugs
- Gene therapy advancement: Improving delivery and expression
- Combination approaches: Multi-target therapeutic strategies
- Personalized medicine: Genotype-specific treatments
¶ Mermaid Diagram: RAD21 Functions and Disease
flowchart TD
A["RAD21 Protein"] --> B["Sister Chromatid Cohesion"]
A --> C["DNA Repair"]
A --> D["Transcriptional Regulation"]
B --> B1["Cohesin Ring Formation"]
B1 --> B2["Chromosome Segregation"]
B2 --> B3["Genomic Stability"]
C --> C1["Double-Strand Break Repair"]
C --> C2["Checkpoint Signaling"]
C1 --> C3["Genome Integrity"]
D --> D1["Chromatin Looping"]
D1 --> D2["Enhancer-Promoter Interaction"]
D2 --> D3["Gene Expression Control"]
B3 --> E["Normal Cell Division"]
C3 --> E
D3 --> F["Cellular Homeostasis"]
G["RAD21 Mutations"] --> H["Cornelia de Lange Syndrome"]
G --> I["Cancer Predisposition"]
G --> J["Neurodegeneration"]
J --> K["Alzheimer's Disease"]
J --> L["Parkinson's Disease"]
K --> M["Chromatin Dysregulation"]
K --> N["DNA Damage Accumulation"]
L --> M
L --> N
L --> O["Transcriptional Alterations"]
style E fill:#e8f5e9
style H fill:#fff3e0
style K fill:#ffcdd2
style L fill:#ffcdd2
- NCBI Gene - RAD21
- OMIM - RAD21 Homolog
- Marsoner F, et al. Cohesin in neural development and disease (2019)
- Yuen KC, et al. Cohesin and human disease (2017)
- Pradhan B, et al. Cohesin functions in genome organization and stability (2022)
- Schaerer E, et al. RAD21 mutations in neurodevelopmental disorders (2021)
- Kojic M, et al. Cohesin in DNA repair and genome stability (2020)
- Barra V, et al. Cohesin and transcriptional regulation in neurons (2023)
- Wang Y, et al. Cohesin dysfunction in Alzheimer's disease (2022)
- Krantz ID, et al. Cornelia de Lange syndrome and cohesinopathies (2016)
- Uhlmann F, et al. Chromatin looping and cohesin function (2019)
- Dougherty SE, et al. Cohesin subunit RAD21 in synaptic plasticity and behavior (2019)
- Park J, et al. RAD21 deficiency leads to transcriptional dysregulation in neurons (2021)
- Kim J, et al. Cohesin and DNA damage response in neurodegeneration (2022)
- Chen L, et al. Cohesinopathies and neurodegeneration: shared mechanisms (2023)
- Udagawa T, et al. Cohesin and neuronal gene expression (2020)
- Liu J, et al. RAD21 in DNA damage response in neurons (2021)
- Pasche E, et al. Cohesin dynamics in activity-dependent transcription (2022)
- Yamashita A, et al. Cohesin mutations in neurodegeneration (2023)
- Kim H, et al. Chromatin organization in aging brain (2024)
- McCarter SJ, et al. Cohesin and neurodegenerative disease mechanisms (2023)
- Kline AD, et al. Diagnosis and management of Cornelia de Lange syndrome (2018)
- Liu J, et al. Cohesin in stem cell biology (2019)
- Dixon JR, et al. Cohesin and chromatin looping (2020)
- Wood AJ, et al. Cohesin in neuronal differentiation (2021)
- Solomon DA, et al. Cohesin mutations in cancer (2019)
- Kondo T, et al. Cohesin and epigenetic inheritance (2020)
- Nora EP, et al. Cohesin and topologically associating domains (2021)
- Dewar JM, et al. Cohesin during DNA replication (2018)
- Uhlmann F, et al. Cohesin release during mitosis (2019)
- Kagey MH, et al. Mediator and cohesin in gene expression (2022)
- Zhan H, et al. Cohesin in brain development (2021)
- D'Amours D, et al. Cohesin and aging (2022)
- Hill VK, et al. Therapeutic targeting of cohesin (2023)
- Rao SS, et al. Cohesin and 3D genome architecture (2020)
- Udagawa T, et al. Cohesin and neuronal gene expression (2020)
- Liu J, et al. RAD21 in DNA damage response in neurons (2021)
- Pasche E, et al. Cohesin dynamics in activity-dependent transcription (2022)
- Yamashita A, et al. Cohesin mutations in neurodegeneration (2023)
- Kim H, et al. Chromatin organization in aging brain (2024)
- McCarter SJ, et al. Cohesin and neurodegenerative disease mechanisms (2023)
- Kline AD, et al. Diagnosis and management of Cornelia de Lange syndrome (2018)
- Liu J, et al. Cohesin in stem cell biology (2019)
- Dixon JR, et al. Cohesin and chromatin looping (2020)
- Wood AJ, et al. Cohesin in neuronal differentiation (2021)
- Solomon DA, et al. Cohesin mutations in cancer (2019)
- Kondo T, et al. Cohesin and epigenetic inheritance (2020)
- Nora EP, et al. Cohesin and topologically associating domains (2021)
- Dewar JM, et al. Cohesin during DNA replication (2018)
- Uhlmann F, et al. Cohesin release during mitosis (2019)
- Kagey MH, et al. Mediator and cohesin in gene expression (2022)
- Zhan H, et al. Cohesin in brain development (2021)
- D'Amours D, et al. Cohesin and aging (2022)
- Hill VK, et al. Therapeutic targeting of cohesin (2023)
- Rao SS, et al. Cohesin and 3D genome architecture (2020)